At the frontier of biomedical publication: Chicago 2005

Abstract

macrovascular events, it is surprising that it had no effect on all cause mortality, especially given that over 350 deaths were observed in the trial. Further reviewThe results of the trial will be published in the Lancet.Publication should enable a more informed and detailed debate on the safety and efficacy of pioglitazone in poorly controlled type 2 diabetes, and, hopefully, a shift from sound bite to science.Contributors and sources: NF has worked as the study statistician on several drug and device trials in diabetes and other clinical areas.He has undertaken methodological work in the interpretation of clinical trials and the use of composite outcome measures.He was in the audience for the presentation of the Proactive study, and the article arose from this and subsequent discussions.Competing interests:

Cite this work

No public copy is stored for this record, so only the metadata is cited.

Stored only when both papers are in the corpus — 14 citations exist upstream.

Papers that cite the same references — the relational fallback while embeddings are still backfilling.